WINTOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
WINDTREE THERAPEUTICS INC /DE/
Financials through Q3 FY2025, quarter ended Sep 30, 2025Last filing: 10-Q on Nov 19, 2025
$0.00+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $26.68K
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2010 to 2024
Gross margin
–
Operating margin
–
Net margin
–
Growth rates
Compound annual growth to fiscal 2024
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2015 | FY2019 | FY2024 | Trend |
|---|---|---|---|---|
| Return on equity | -401.7% | -38.4% | -26.7% | |
| Return on assets | -120.1% | -23.1% | -5.9% | |
| Current ratio | 3.69 | 3.05 | 0.45 | |
| Debt to equity | 3.02 | – | – | |
| Net debt to EBITDA | 0.36× | – | – | |
| Interest coverage | -8.7× | -50.3× | -111.2× | |
| Capex to revenue | 46.4% | 96.5% | – | |
| Diluted shares | 0M | 0M | 53M |
Where the cash went
Fiscal 2020 to 2024, five years combined
Windtree Therapeutics generated $97.27M from operations and spent $1.27M on capital expenditure, dividends and share buybacks. 48% of that went back into the business.
Generated
$97.27M
Used
$1.27M
Capital expenditure$610.00K48%Dividends$657.00K52%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-13876.3%
×Asset turnover0.00×
×Equity multiplier1.67×
=Return on equity, FY2019-38.4%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2019 | -13876.3% | 0.00× | 1.67× | -38.4% |
| FY2018 | -1148.4% | 0.03× | 2.78× | -92.9% |
| FY2017 | -1242.2% | 0.23× | -0.25× | 69.9% |
| FY2016 | -1933.9% | 0.08× | -2.63× | 384.1% |
| FY2015 | -5589.7% | 0.02× | 3.35× | -401.7% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2024 against fiscal 2023
1of 6 tests passed in fiscal 2024. Some tests lack the figures they need.
- ProfitableNet income above zero-$1.79M
- Cash generatingOperating cash flow above zero-$15.40M
- Return on assets improvedROA up on the prior year-53.5% → -5.5%
- Earnings backed by cashOperating cash flow above net income-$15.40M vs -$1.79M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose1.35 → 0.45
- No dilutionShare count did not rise4M → 53M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –